ANI Pharmaceuticals Reports Second Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
ANI Pharma (ANIP) Misses Q2 EPS by 1c
August 6, 2021 7:25 AM EDTANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $0.67, $0.01 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $48.05 million.
For earnings history and earnings-related data on ANI Pharma (ANIP) click here.
... More